# Standard Biotools Inc.: overview

LAB · Nasdaq · CIK 1162194 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lab.md) · [Financials](/companies/lab/financials.md) · [Filings](/companies/lab/filings.md) · [Insiders](/companies/lab/insiders.md)

Latest reported revenue: [$20.1m](/filings/0001193125-26-335103.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335103).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [22.1](/filings/0001193125-25-264695.md) | [24.8 d](/filings/0001193125-26-108326.md) | [20.2](/filings/0001193125-26-208967.md) | [21.8](/filings/0001193125-26-335103.md) | [19.6](/filings/0001193125-25-264695.md) | [23.8 d](/filings/0001193125-26-108326.md) | [21.1](/filings/0001193125-26-208967.md) | [20.1](/filings/0001193125-26-335103.md) |
| Gross margin | % | [54.9%](/filings/0001193125-25-264695.md) | [45.8% d](/filings/0001193125-26-108326.md) | [54.6%](/filings/0001193125-26-208967.md) | [48.8%](/filings/0001193125-26-335103.md) | [48.5%](/filings/0001193125-25-264695.md) | [47.8% d](/filings/0001193125-26-108326.md) | [53.5%](/filings/0001193125-26-208967.md) | [52.4%](/filings/0001193125-26-335103.md) |
| Operating margin | % | [(120.9%)](/filings/0001193125-25-264695.md) | [(105.3%) d](/filings/0001193125-26-108326.md) | [(133.4%)](/filings/0001193125-26-208967.md) | [(118.1%)](/filings/0001193125-26-335103.md) | [(168.5%)](/filings/0001193125-25-264695.md) | [(103.6%) d](/filings/0001193125-26-108326.md) | [(59.1%)](/filings/0001193125-26-208967.md) | [(126.3%)](/filings/0001193125-26-335103.md) |
| Net margin | % | [(122.0%)](/filings/0001193125-25-264695.md) | [(137.5%) d](/filings/0001193125-26-108326.md) | [(128.7%)](/filings/0001193125-26-335103.md) | [(153.7%)](/filings/0001193125-26-335103.md) | [(177.4%)](/filings/0001193125-25-264695.md) | [81.0% d](/filings/0001193125-26-108326.md) | [600.9%](/filings/0001193125-26-335103.md) | [(133.1%)](/filings/0001193125-26-335103.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0001193125-25-264695.md) | not reported | [(0.07)](/filings/0001193125-26-208967.md) | [(0.09)](/filings/0001193125-26-335103.md) | [(0.09)](/filings/0001193125-25-264695.md) | not reported | [0.33](/filings/0001193125-26-208967.md) | [(0.07)](/filings/0001193125-26-335103.md) |
| Free cash flow | $m | [(30.1) d](/filings/0001193125-25-264695.md) | [(17.4) d](/filings/0001193125-26-108326.md) | [(35.3)](/filings/0001193125-26-208967.md) | [(22.6) d](/filings/0001193125-26-335103.md) | [(23.1) d](/filings/0001193125-25-264695.md) | [(1.7) d](/filings/0001193125-26-108326.md) | [(47.2)](/filings/0001193125-26-208967.md) | [(10.7) d](/filings/0001193125-26-335103.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [131](/filings/0001162194-23-000013.md) | [97.9](/filings/0000950170-25-036608.md) | [106](/filings/0001193125-26-108326.md) | [91.0](/filings/0001193125-26-108326.md) | [85.3](/filings/0001193125-26-108326.md) |
| Gross margin | % | not reported | [37.8%](/filings/0000950170-25-036608.md) | [47.4%](/filings/0001193125-26-108326.md) | [49.3%](/filings/0001193125-26-108326.md) | [49.9%](/filings/0001193125-26-108326.md) |
| Operating margin | % | [(51.7%)](/filings/0001162194-23-000013.md) | [(118.6%)](/filings/0000950170-25-036608.md) | [(72.0%)](/filings/0001193125-26-108326.md) | [(140.1%)](/filings/0001193125-26-108326.md) | [(129.2%)](/filings/0001193125-26-108326.md) |
| Net margin | % | [(45.4%)](/filings/0001162194-23-000013.md) | [(194.1%)](/filings/0000950170-25-036608.md) | [(70.2%)](/filings/0001193125-26-108326.md) | [(152.6%)](/filings/0001193125-26-108326.md) | [(87.8%)](/filings/0001193125-26-108326.md) |
| Diluted EPS | $ per share | [(0.78)](/filings/0001162194-23-000013.md) | [(2.43)](/filings/0000950170-25-036608.md) | [(0.94)](/filings/0001193125-26-108326.md) | [(0.52)](/filings/0001193125-26-108326.md) | [(0.20)](/filings/0001193125-26-108326.md) |
| Free cash flow | $m | [(57.3)](/filings/0001162194-23-000013.md) | [(93.2)](/filings/0000950170-25-036608.md) | [(46.1)](/filings/0001193125-26-108326.md) | [(152)](/filings/0001193125-26-108326.md) | [(82.6)](/filings/0001193125-26-108326.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Gross profit: us-gaap:GrossProfit.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lab/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Casdin Capital, LLC](/funds/1534261.md) | 2026-06-30 | $73.0m | 88,783,856 |  | Unchanged |
| [VIKING GLOBAL INVESTORS LP](/funds/1103804.md) | 2026-06-30 | $48.3m | 58,651,170 |  | Unchanged |
| [MAK CAPITAL ONE LLC](/funds/1385702.md) | 2026-06-30 | $23.7m | 28,813,904 |  | Added +2,641,278 |
| [Long Focus Capital Management, LLC](/funds/1602716.md) | 2026-06-30 | $19.3m | 23,500,000 |  | Added +7,484,279 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $10.1m | 12,252,998 |  | Reduced −563,072 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $6.8m | 8,254,443 |  | Reduced −16,501,641 |
| [Hollow Brook Wealth Management LLC](/funds/1455251.md) | 2026-06-30 | $4.5m | 5,503,381 |  | Reduced −150,000 |
| [NEUBERGER BERMAN GROUP LLC](/funds/1465109.md) | 2026-06-30 | $4.0m | 4,958,620 |  | Added +301,035 |
| [Qube Research & Technologies Ltd](/funds/1729829.md) | 2026-06-30 | $4.0m | 4,820,463 |  | Added +4,116,056 |
| [ROYCE & ASSOCIATES LP](/funds/906304.md) | 2026-06-30 | $3.7m | 4,525,333 |  | Added +1,519,804 |

## Recent filings

[All 1,567 filings](/companies/lab/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-05 | 20:16 ET | [8-K](/filings/0001140361-26-038624.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-038624 |
| 2026-09-30 | 21:27 ET | [8-K](/filings/0001140361-26-038110.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-038110 |
| 2026-08-05 | 20:10 ET | [10-Q](/filings/0001193125-26-335103.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335103 |
| 2026-08-05 | 20:10 ET | [8-K](/filings/0001193125-26-335106.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-335106 |
| 2026-07-29 | 12:15 ET | [8-K/A](/filings/0001140361-26-029964.md) | 9.01 Financial statements and exhibits | 0001140361-26-029964 |
| 2026-07-28 | 12:20 ET | [8-K](/filings/0001140361-26-029841.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-029841 |
| 2026-07-24 | 20:38 ET | [8-K](/filings/0001193125-26-316183.md) | 3.01 Delisting notice | 0001193125-26-316183 |
| 2026-06-18 | 20:30 ET | [8-K](/filings/0001193125-26-275946.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-275946 |
| 2026-06-12 | 21:35 ET | [SCHEDULE 13D](/filings/0000905148-26-002940.md) | Ownership report, active investor | 0000905148-26-002940 |
| 2026-06-09 | 21:41 ET | [SCHEDULE 13D/A](/filings/0000919574-26-003923.md) | Ownership report, active investor, amended | 0000919574-26-003923 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-108326.md), filed Mar 16, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/69347d87-d013-428d-ae1e-43b644bf2b42)

## About the filer

- CIK: 1162194
- Tickers: LAB
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.